Commonly prescribed pain drug can increase your risk of dementia by up to 40%
The anti-seizure drug gabapentin is used to treat epilepsy, nerve pain after shingles and restless legs syndrome by affecting chemical messengers in the brain and nerves.
Common side effects include dizziness, drowsiness, headaches and nausea. Now, a new study out of Case Western Reserve University in Cleveland warns that gabapentin can significantly increase the risk of dementia and mild cognitive impairment in people taking it for chronic low back pain.
4 A new study warns that gabapentin can significantly increase the risk of dementia and mild cognitive impairment in people taking it for chronic low back pain.
ryanking999 – stock.adobe.com
'Our findings indicate an association between gabapentin prescription and dementia or cognitive impairment within 10 years. Moreover, increased gabapentin prescription frequency correlated with dementia incidence,' the study authors wrote this week in the journal Regional Anesthesia & Pain Medicine.
Researchers pored over records of 26,400 patients who had been prescribed gabapentin for persistent low back pain between 2004 and 2024 and 26,400 patients who didn't get a prescription.
After taking into account patient demographics, their medical history and their use of other painkillers, the researchers determined that those who had received six or more gabapentin prescriptions were 29% more likely to be diagnosed with dementia.
This same group was also 85% more likely to be diagnosed with mild cognitive impairment within 10 years of their back pain diagnosis.
4 The anti-seizure drug gabapentin is used to treat epilepsy, nerve pain after shingles and restless legs syndrome by affecting chemical messengers in the brain and nerves.
The Drug Users Bible
Dementia tends to affect older adults, yet the risks of dementia more than doubled among 35- to 49-year-olds prescribed gabapentin.
Their risks of mild cognitive impairment more than tripled.
Similar effects were seen in patients 50 to 64 years old.
Frequency of use was an important factor, too.
People with 12 or more prescriptions were 40% more likely to develop dementia and 65% more likely to develop mild cognitive impairment than those prescribed gabapentin three to 11 times.
Gabapentin was approved by the US Food and Drug Administration in 1993 to control partial seizures in epilepsy patients older than 12.
4 Gabapentin was approved by the US Food and Drug Administration in 1993 to control partial seizures in epilepsy patients older than 12.
W.carter/Wikimedia Commons
Unlike opioids, gabapentin was initially considered to have a low potential for abuse or dependence.
However, there's growing concern about its misuse, particularly to enhance opioid highs.
With this new research, the study authors acknowledged that their work was observational, so they could not definitively establish a cause-and-effect relationship between gabapentin and dementia.
They also noted that they weren't able to account for gabapentin dose or length of use in their records review.
Still, they said their 'results support the need for close monitoring of adult patients prescribed gabapentin to assess for potential cognitive decline.'
4 Dementia, which affects over 6 million Americans, is characterized by troubles with memory, problem-solving, judgment and language.
LIGHTFIELD STUDIOS – stock.adobe.com
Other medical experts cautioned against drawing overly strong conclusions from the findings.
'While authors used statistical methods to try and account for other risk factors, this type of study cannot prove that gabapentin was the cause of increased dementia risk,' Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh in Scotland, told reporters.
'One very important factor that was not examined in this study is levels of physical activity,' she added. 'People with chronic pain requiring gabapentin may have been less physically active, which is a known risk factor for developing dementia.'
Other known risk factors for dementia include traumatic brain injury, untreated hearing loss, depression, high blood pressure, diabetes, obesity and a history of smoking.
Experts recommend lowering dementia risk with a healthy diet, regular exercise and social activity and without cigarettes or excessive alcohol.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
4 days ago
- Los Angeles Times
Lawmakers press FDA to target knockoff weight-loss drug
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartis an lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. Muller writes for Bloomberg.
Yahoo
4 days ago
- Yahoo
MeMed develops rapid infection differentiation test
MeMed has developed MeMed BV Flex, a rapid infection differentiation test that distinguishes between bacterial and viral infections. This test is set to widen the accessibility of MeMed BV to decentralised, Clinical Laboratory Improvement Amendments (CLIA)-waived settings, using a few drops of blood from a finger prick to deliver results within 15 minutes. Designed for near-patient use, the test operates on an improved version of MeMed's current platform. It has been verified in a prospective analytical trial, showing performance on par with laboratory methods. According to the published study, measurements of capillary and venous blood demonstrated high concordance in terms of all the host proteins examined, along with the MeMed BV score, suggesting that there is alignment between the sample types. The company noted that a multi-centre pivotal trial is currently underway to support regulatory submission and confirm clinical accuracy, following initial discussions with the US Food and Drug Administration (FDA). By using host response data, MeMed BV aims to aid physicians with the information needed to make informed treatment decisions and decrease needless antibiotic use. MeMed CEO and co-founder Eran Eden said: 'Accurately and simultaneously measuring multiple proteins from just a few drops of blood, in a rapid and easy-to-use format, has been a long-standing challenge. 'By pairing this breakthrough with machine learning, we've enhanced our platform, which, once cleared, can help extend host-response testing across broader decentralised use. It's a major step toward our next goal of reaching one million patients and enables a plug-and-play engine for our broader pipeline, from MeMed Severity to future sepsis and immune-status assays.' Last year, MeMed secured the FDA's breakthrough device designation for its MeMed Severity test, which is designed to improve the management of patients with suspected acute infections and sepsis. "MeMed develops rapid infection differentiation test" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
CNN
5 days ago
- CNN
100 days into the job, FDA Commissioner talks to CNN about staff changes, agency process— and Coke's switch to sugar
The US Food and Drug Administration is plowing ahead with sweeping plans to crack down on ultra processed foods and reshape the way new drugs and devices are reviewed and approved, the agency's commissioner, Marty Makary, told CNN in an interview this week. Makary sat down with CNN at the FDA's White Oak, Maryland campus, roughly 100 days into his tenure as the head of the agency that oversees vast portions of the US's food and health system: drugs, medical devices, tobacco and a portion of the food supply that accounts for roughly a fifth of the US economy. In the large, sunny room overlooking the courtyard at the center of the FDA's sprawling grounds, Makary put forth talking points he has often repeated on his podcast, 'FDA Direct'— a new feature for a commissioner. In a wide-ranging interview, he addressed everything from the agency's staffing changes to his thoughts on Coca-Cola's switch to real sugar. Makary, a gastrointestinal surgeon, took over the FDA just as broad layoffs and a slew of departures of experienced senior staff hit the agency amid changes orchestrated by DOGE, a White House efficiency group that attempted to reform the federal government through dramatic cuts. Makary was sworn in on the same day that the cuts took place, April 1. The FDA has since reinstated 'hundreds' of those terminated employees, Makary told CNN on Monday, and the waters have calmed since the layoffs. 'I want the public to know something very clear,' Makary said. 'The FDA is strong, and it will continue to be strong. The trains are running on time,' he said. 'We're going to meet all our targets this year,' he said, referring to the number of drugs and devices the FDA aims to evaluate by January. Such an achievement, if met, would be a relief for the US pharmaceutical industry, which has been watching cautiously as the agency overhauls its regulatory process, promising speedy new pathways for approvals. There has been skepticism. Earlier this year, hundreds of biotech executives had publicly lamented that FDA's leadership on science would be 'irretrievably lost' because of the April staffing losses. While scientists reviewing new drugs and devices were spared from cuts, administrative staff who aid their work were not. Since Makary assumed his post, the FDA also rolled out Elsa, a new artificial intelligence chatbot billed as a tool to help staff speed up clinical reviews and scientific evaluations. But Elsa has made up nonexistent studies and gotten facts wrong, according to six current and former FDA officials who spoke to CNN. Asked about the potential risks of AI-aided review, Makary said it is a work in progress. 'We never want to miss something that could be dangerous,' he said. 'It is a balancing act, and we've got to continue to try to do it.' The FDA is also a critical part of Health Secretary Robert F. Kennedy Jr.'s vision to 'Make America Healthy Again' through food policy reforms. This week, the US Department of Health and Human Services, which oversees the FDA, took a first major step toward regulating ultra processed foods by asking industry and scientific experts for feedback on how to define them. A major tenet of Kennedy's MAHA agenda is to remove artificial ingredients from foods, overhaul prescription drug use and tackle environmental toxins, all of which he believes are driving chronic illness among American children. Speaking to CNN, Makary laid out a framework for the FDA's broader food policy plans, including dramatic changes to the federal dietary guidelines, a compass for doctors, schools and families on the foods to eat and avoid. They are 'cleaning house' on the guidelines, Makary said. 'We're going to go bold on this because for too long, people have been confused, they've been misled.' 'We have a public trust epidemic in health care because in part people were lied to about what's healthy and what's not healthy,' he said — an assertion that would be highly disputed by experts who advise on the guidelines every five years. Moreover, the dietary guidelines are not entirely up to Makary and his agency. They'll have to hammer out the final recommendations by December with the US Department of Agriculture, and there has already been friction. Makary is also determined to see an end to what he called 'the 70-year war on natural saturated fat'— a substance, he says, that has 'never been found in any clinical trial to be directly associated with heart disease.' That claim is disputable. While Makary did not elaborate on which types of natural saturated fat have been demonized, as he put it, nutrition experts have said there are still significant and well-established harms to heart health from fats in red and processed meats. In dairy, different saturated fats are thought to have varied levels of risk and benefit. Makary's comments come as major food companies and fast-food chains scramble to position themselves as MAHA allies, promising to remove artificial ingredients and food dyes, and switch out seed oils for Kennedy's favored frying ingredient, beef tallow. Coca-Cola announced last week that it would start offering products with cane sugar rather than high-fructose corn syrup, news that was heralded by President Donald Trump. Experts say that is a marginal change; both are ultimately bad for your health. Asked about Coke's sugar announcement, Makary said, 'There are incremental benefits to the different types of sugar out there' but that 'I think it's a good switch.' There is more to come. The commissioner also said that FDA is 'doing an inventory' of more than 11,000 chemicals that are banned in Europe and other countries, but 'common' in the US food supply. Before coming to the FDA, Makary, a surgeon at Johns Hopkins University, was probably best known for a series of books on flaws in the health care system. He supported lockdowns and masking in the early days of the Covid-19 pandemic, but later became a prominent critic of vaccine requirements and booster shots. He argued in a February 2021 Wall Street Journal op-ed that the US would reach herd immunity by that April; instead, new waves of Covid strains hit the population. Those views did not exactly alienate Makary from the medical establishment or Washington's political world. Three Democratic senators voted to confirm him, making him the only one of Trump's health nominees to win Democratic votes in this administration. 'The day before my Senate confirmation hearing, I was in the operating room. So this is an entirely different domain for me,' Makary said. Sandee LaMotte contributed to this report.
